New number of shares and votes in Biovitrum AB (publ)

The total number of shares in Biovitrum AB (publ) as per 30 September
2009 amounts to in total 50,911,901 shares, whereof 50,396,316 common
shares  and  515,585  class  C  shares,  corresponding  to  in  total
50,447,874.5 votes. The increase  in the number  of shares and  votes
results from an  issue of  231,585 class C  shares under  Biovitrum's
long term performance  based share  program. The class  C shares  are
intended to secure delivery of shares under the program.


For more information please contact:

Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com


About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions. Using its expertise
and experience Biovitrum takes scientific innovation to patients with
significant unmet medical need. Research expertise and capabilities
are focused on development and production of biotechnology
therapeutics within our prioritized areas of hemophilia,
inflammation/autoimmune diseases, cancer supportive care and
malabsorption. The company has revenues of approximately SEK 1.2
billion and around 400 employees. The company head office is located
in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For
more information please visit  www.biovitrum.com


Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on September 30, 2009 at
11:30 a.m. CET.